HIPK2 phosphorylates Δnp63α and promotes its degradation in response to DNA damage

Oncogene

Volumn 30, Issue 48, 2011, Pages 4802-4813

  Lazzari, C ^a   Prodosmo, A ^a   Siepi, F ^a   Rinaldo, C ^a   Galli, F ^b   Gentileschi, M ^a   Bartolazzi, A ^c,d   Costanzo, A ^e   Sacchi, A ^a   Guerrini, L ^b   Soddu, S ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Chemotherapy; Degradation; DNp63; HIPK2; Phosphorylation

Indexed keywords

ANTINEOPLASTIC AGENT; HOMEODOMAIN INTERACTING PROTEIN KINASE 2; PROTEASOME; PROTEIN P53; PROTEIN P63;

ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DNA DAMAGE; DRUG RESISTANCE; ENZYME ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; TUMOR CELL;

ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; DNA DAMAGE; DOXORUBICIN; HUMANS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTEOLYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 82455209036     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.182     Document Type: Article

References (63)

1. Barbieri CE, Perez CA, Johnson KN, Ely KA, Billheimer D, Pietenpol JA. (2005). IGFBP-3 is a direct target of transcriptional regulation by DeltaNp63alpha in squamous epithelium. Cancer Res 65: 2314-2320. (Pubitemid 40490141)
2. Bon G, Di Carlo SE, Folgiero V, Avetrani P, Lazzari C, D'Orazi G et al. (2009). Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression. Cancer Res 691: 5978-5986.
3. Bracaglia G, Conca B, Bergo A, Rusconi L, Zhou Z, Greenberg ME et al. (2009). Methyl-CpG-binding protein 2 is phosphorylated by homeodomain- interacting protein kinase 2 and contributes to apoptosis. EMBO Rep 10: 1327-1333.
4. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP et al. (1998). Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501. (Pubitemid 28538613)
5. Calzado MA, De La Vega L, Munoz E, Schmitz ML. (2009). From top to bottom: the two faces of HIPK2 for regulation of the hypoxic response. Cell Cycle 8: 1659-1664.
6. Calzado MA, Renner F, Roscic A, Schmitz ML. (2007). HIPK2: a versatile switchboard regulating the transcription machinery and cell death. Cell Cycle 15: 139-143. (Pubitemid 46232491)
7. Carroll DK, Carroll JS, Leong CO, Cheng F, Brown M, Mills AA et al. (2006). p63 regulates an adhesion programme and cell survival in epithelial cells. Nat Cell Biol 8: 551-561. (Pubitemid 43827347)
8. Cecchinelli B, Lavra L, Rinaldo C, Iacovelli S, Gurtner A, Gasbarri A et al. (2006a). Repression of the antiapoptotic molecule galectin-3 by homeodomain-interacting protein kinase 2-activated p53 is required for p53-induced apoptosis. Mol Cell Biol 26: 4746-4757. (Pubitemid 43877589)
9. Cecchinelli B, Porrello A, Lazzari C, Gradi A, Bossi G, D'Angelo M et al. (2006b). Ser58 of mouse p53 is the homologue of human Ser46 and is phosphorylated by HIPK2 in apoptosis. Cell Death Differ 13: 1994-1997. (Pubitemid 44542411)
10. Ciardiello F, McGeady ML, Kim N, Basolo F, Hynes N, Langton BC et al. (1990). Transforming growth factor-alpha expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factoralpha complementary DNA leads to transformation. Cell Growth Differ 1: 407-420.
11. Dauth I, Kruger J, Hofmann TG. (2007). Homeodomain-interacting protein kinase 2 is the ionizing radiation-activated p53 serine 46 kinase and is regulated by ATM. Cancer Res 67: 2274-2279. (Pubitemid 46424247)
12. Di Costanzo A, Festa L, Duverger O, Vivo M, Guerrini L, La Mantia G et al. (2009). Homeodomain protein Dlx3 induces phosphorylation-dependent p63 degradation. Cell Cycle 8: 1185-1195.
13. Di Stefano V, Rinaldo C, Sacchi A, Soddu S, D'Orazi G. (2004). Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis. Cell Res 293: 311-320. (Pubitemid 38083221)
14. D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S et al. (2002). Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol 4: 11-19.
15. Du Z, Li J, Wang L, Bian C, Wang Q, Liao L et al. (2010). Overexpression of DNp63α induces a stem cell phenotype in MCF7 breast carcinoma cell line through the Notch pathway. Cancer Sci 101: 2417-2424.
16. Fomenkov A, Zangen R, Huang YP, Osada M, Guo Z, Fomenkov T et al. (2004). RACK1 and stratifin target DeltaNp63alpha for a proteasome degradation in head and neck squamous cell carcinoma cells upon DNA damage. Cell Cycle 3: 1285-1295. (Pubitemid 40268612)
17. Galli F, Rossi M, D'Alessandra Y, De Simone M, Lopardo T, Haupt Y et al. (2010). MDM2 and Fbw7 cooperate to induce p63 protein degradation following DNA damage and cell differentiation. J Cell Sci 123: 2423-2433.
18. Gonfloni S, Di Tella L, Caldarola S, Cannata SM, Klinger FG, Di Bartolomeo C et al. (2009). Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. Nat Med 15: 1179-1185.
19. Gresko E, Ritterhoff S, Sevilla-Perez J, Roscic A, Frobius K, Kotevic I et al. (2009). PML tumor suppressor is regulated by HIPK2-mediated phosphorylation in response to DNA damage. Oncogene 28: 698-708.
20. Gresko E, Roscic A, Ritterhoff S, Vichalokovski A, Del Sal G, Schimtz ML. (2006). Autoregulatory control of the p53 response by caspase-mediated processing of HIPK2. EMBO J 25: 1883-1894.
21. Hibi K, Trink B, Patturajan M, Westra WH, Caballero OL, Hill DE et al. (2000). AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci USA 97: 5462-5467. (Pubitemid 30313741)
22. Hofmann TG, Möller A, Sirma H, Zentgraf H, Taya Y, Dröge W et al. (2002). Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol 4: 1-10. (Pubitemid 34071974)
23. Hofmann TG, Stollberg N, Schmitz ML, Will H. (2003). HIPK2 regulates transforming growth factor-beta-induced c-Jun NH(2)-terminal kinase activation and apoptosis in human hepatoma cells. Cancer Res 63: 8271-8277. (Pubitemid 37549478)
24. Huang Y, Chuang AY, Romano RA, Liégeois NJ, Sinha S, Trink B et al. (2010). Phospho-DeltaNp63alpha/NF-Y protein complex transcriptionally regulates DDIT3 expression in squamous cell carcinoma cells upon cisplatin exposure. Cell Cycle 9: 328-338.
25. Huang Y, Sen T, Nagpal J, Upadhyay S, Trink B, Ratovitski E et al. (2008). ATM kinase is a master switch for the Delta Np63 alpha phosphorylation/degradation in human head and neck squamous cell carcinoma cells upon DNA damage. Cell Cycle 7: 2846-2855.
26. Irwin MS, Kaelin WG. (2001). p53 family update: p73 and p63 develop their own identities. Cell Growth Differ 12: 337-349. (Pubitemid 32685635)
27. Kanei-Ishii C, Ninomiya-Tsuji J, Tanikawa J, Nomura T, Ishitani T, Kishida S et al. (2004). Wnt-1 signal induces phosphorylation and degradation of c-Myb protein via TAK1, HIPK2, and NLK. Genes Dev 18: 816-829. (Pubitemid 38480893)
28. Kim EJ, Park JS, Um SJ. (2002). Identification and characterization of HIPK2 interacting with p73 and modulating functions of the p53 family in vivo. J Biol Chem 277: 32020-32028.
29. Kim YH, Choi CY, Lee SJ, Conti MA, Kim Y. (1998). Homeodomaininteracting protein kinases, a novel family of co-repressors for homeodomain transcription factors. J Biol Chem 273: 25875-25879. (Pubitemid 28475817)
30. Lanza M, Marinari B, Papoutsaki M, Giustizieri ML, D'Alessandra Y, Chimenti S et al. (2006). Cross-talks in the p53 family: deltaNp63 is an anti-apoptotic target for deltaNp73alpha and p53 gain-offunction mutants. Cell Cycle 5: 1996-2004. (Pubitemid 44435307)
31. Lavra L, Rinaldo C, Ulivieri A, Luciani E, Fidanza P, Giacomelli L et al. (2011). The loss of the p53 activator HIPK2 is responsible for Galectin-3 overexpression in well differentiated thyroid carcinomas. PLoS ONE (in press).
32. Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW. (2007). The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 117: 1370-1380. (Pubitemid 46718425)
33. Li Q, Lin S, Wang X, Lian G, Lu Z, Guo H et al. (2009). Axin determines cell fate by controlling the p53 activation threshold after DNA damage. Nat Cell Biol 11: 1128-1134.
34. Li XL, Arai Y, Harada H, Shima Y, Yoshida H, Rokudai S et al. (2007). Mutations of the HIPK2 gene in acute myeloid leukemia and myelodysplastic syndrome impair AML1- and p53-mediated transcription. Oncogene 26: 7231-7239. (Pubitemid 350085316)
35. Li Y, Zhou Z, Chen C. (2008). WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitinmediated proteasomal degradation and regulates apoptosis. Cell Death Differ 15: 1941-1951.
36. Liefer KM, Koster MI, Wang XJ, Yang A, McKeon F, Roop DR. (2000). Down-regulation of p63 is required for epidermal UV-Binduced apoptosis. Cancer Res 60: 4016-4020. (Pubitemid 30636575)
37. Lin Z, Liu M, Li Z, Kim C, Lee E, Kim I. (2006). DeltaNp63 protein expression in uterine cervical and endometrial cancers. J Cancer Res Clin Oncol 32: 811-816. (Pubitemid 44521457)
38. MacPartlin M, Zeng SX, Lu H. (2008). Phosphorylation and stabilization of TAp63gamma by IkappaB kinase-beta. J Biol Chem 283: 15754-15761.
39. Moll UM, Slade N. (2004). p63 and p73: roles in development and tumor formation. Mol Cancer Res 2: 371-386. (Pubitemid 39031071)
40. Muller M, Elisa Schleithoff S, Stremmel W, Melino G, Krammer PH, Schilling T. (2006). One, two, three-p53, p63, p73 and chemosensitivity. Drug Res Updates 9: 288-306.
41. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T et al. (2000). p53-AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102: 849-862.
42. Papoutsaki M,Moretti F, Lanza M, Marinari B, Sartorelli V, Guerrini L et al. (2005). A p38-dependent pathway regulates DeltaNp63 DNA binding to p53-dependent promoters in UV-induced apoptosis of keratinocytes. Oncogene 24: 6970-6975. (Pubitemid 41509419)
43. Parsa R, Yang A, McKeon F, Green H. (1999). Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. J Invest Dermatol 113: 1099-1105. (Pubitemid 30013359)
44. Pierantoni GM, Rinaldo C, Mottolese M, Di Benedetto A, Esposito F, Soddu S et al. (2007). High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. J Clin Invest 17: 693-702. (Pubitemid 46348527)
45. Puca R, Nardinocchi L, Gal H, Rechavi G, Amariglio N, Domany E et al. (2008). Reversible dysfunction of wild-type p53 following homeodomain- interacting protein kinase-2 knockdown. Cancer Res 68: 3707-3714.
46. Puca R, Nardinocchi L, Givol D, D'Orazi G. (2010). Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells. Oncogene 29: 4378-4387.
47. Rinaldo C, Prodosmo A, Mancini F, Iacovelli S, Sacchi A, Moretti F et al. (2007a). MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis. Mol Cell 25: 739-750. (Pubitemid 46341925)
48. Rinaldo C, Prodosmo A, Siepi F, Soddu S. (2007b). HIPK2: a multitalented partner for transcription factors in DNA damage response and development. Biochem Cell Biol 85: 411-418. (Pubitemid 47518036)
49. Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW. (2006). p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 9: 45-56. (Pubitemid 43069510)
50. Rossi M, Aqeilan RI, Neale M, Candi E, Salomoni P, Knight RA et al. (2006). The E3 ubiquitin ligase Itch controls the protein stability of p63. Proc Natl Acad Sci USA 103: 12753-12758. (Pubitemid 44298633)
51. Senoo M, Tsuchiya I, Matsumura Y, Mori T, Saito Y, Kato H et al. (2001). Transcriptional dysregulation of the p73L/p63/p51/p40/KET gene in human squamous cell carcinomas: expression of Delta Np73L, a novel dominant-negative isoform, and loss of expression of the potential tumour suppressor p51. Br J Cancer 84: 1235-1241. (Pubitemid 32511342)
52. Vilgelm A, El-Rifai W, Zaika A. (2008). Therapeutic prospects for p73 and p63: rising from the shadow of p53. Drug Resist Updat 11: 152-163.
53. Wang N, Guo L, Rueda BR, Tilly JL. (2010). Cables1 protects p63 from proteasomal degradation to ensure deletion of cells after genotoxic stress. EMBO Rep 11: 633-639.
54. Wee HJ, Voon DC, Bae SC, Ito Y. (2008). PEBP2-beta/CBF-betadependent phosphorylation of RUNX1 and p300 by HIPK2: implications for leukemogenesis. Blood 112: 3777-3787.
55. Wesierska-Gadek J, Schmitz ML, Ranftler C. (2007). Roscovitineactivated HIP2 kinase induces phosphorylation of wt p53 at Ser-46 in human MCF-7 breast cancer cells. J Cell Biochem 100: 865-874.
56. Westfall MD, Joyner AS, Barbieri CE, Livingstone M, Pietenpol JA. (2005). Ultraviolet radiation induces phosphorylation and ubiquitin-mediated degradation of Delta Np63alpha. Cell Cycle 4: 710-716. (Pubitemid 41353857)
57. Winter M, Sombroek D, Dauth I, Moehlenbrink J, Scheuermann K, Crone J et al. (2008). Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint kinases ATM and ATR. Nat Cell Biol 10: 812-824. (Pubitemid 351927710)
58. Wu G, Osada M, Guo Z, Fomenkov A, Begum S, Zhao M et al. (2005). DeltaNp63alpha up-regulates the Hsp70 gene in human cancer. Cancer Res 65: 758-766. (Pubitemid 40216433)
59. Yamada D, Pe'rez-Torrado R, Filion G, Caly M, Jammart B, Devignot V et al. (2009). The human protein kinase HIPK2 phosphorylates and downregulates the methyl-binding transcription factor ZBTB4. Oncogene 28: 2535-2544.
60. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V et al. (1998). p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2: 305-316. (Pubitemid 128379271)
61. Yang A, Zhu Z, Kapranov P, McKeon F, Church GM, Gingeras TR et al. (2006). Relationships between p63 binding, DNA sequence, transcription activity, and biological function in human cells. Mol Cell 24: 593-602. (Pubitemid 350284225)
62. Zangen R, Ratovitski E, Sidransky D. (2005). DeltaNp63alpha levels correlate with clinical tumor response to cisplatin. Cell Cycle 4: 1313-1315. (Pubitemid 41437109)
63. Zhang Q, Yoshimatsu Y, Hildebrand J, Frisch SM, Goodman RH. (2003). Homeodomain interacting protein kinase 2 promotes apoptosis by downregulating the transcriptional corepressor CtBP. Cell 115: 177-186. (Pubitemid 37329581)